Valion Bio Inc (VBIO) - Net Assets
Based on the latest financial reports, Valion Bio Inc (VBIO) has net assets worth $16.80 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($31.61 Million) and total liabilities ($14.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Valion Bio Inc total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.80 Million |
| % of Total Assets | 53.14% |
| Annual Growth Rate | 63.92% |
| 5-Year Change | 1845.46% |
| 10-Year Change | N/A |
| Growth Volatility | 224.23 |
Valion Bio Inc - Net Assets Trend (2017–2025)
This chart illustrates how Valion Bio Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Valion Bio Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Valion Bio Inc (2017–2025)
The table below shows the annual net assets of Valion Bio Inc from 2017 to 2025. For live valuation and market cap data, see Valion Bio Inc (VBIO) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $16.80 Million | +562.60% |
| 2024-12-31 | $2.54 Million | -29.19% |
| 2023-12-31 | $3.58 Million | -1.38% |
| 2022-12-31 | $3.63 Million | +320.43% |
| 2020-12-31 | $863.39K | -32.67% |
| 2019-12-31 | $1.28 Million | +297.92% |
| 2017-12-31 | $322.27K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Valion Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3055206000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $69.39 Million | 413.13% |
| Total Equity | $16.80 Million | 100.00% |
Valion Bio Inc Competitors by Market Cap
The table below lists competitors of Valion Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shyam Telecom Limited
NSE:SHYAMTEL
|
$2.55 Million |
|
Green Minerals AS
OL:GEM
|
$2.55 Million |
|
Proteak Uno S.A.B. de C.V
MX:TEAKCPO
|
$2.55 Million |
|
TECIL Chemicals and Hydro Power Limited
NSE:TECILCHEM
|
$2.55 Million |
|
Laxmi Cotspin Limited
NSE:LAXMICOT
|
$2.55 Million |
|
City Of London Investment Group
LSE:CLIG
|
$2.55 Million |
|
Pacific Resources Limited
AU:PXR
|
$2.55 Million |
|
Bathurst Metals Corp
V:BMV
|
$2.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Valion Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,535,000 to 16,797,000, a change of 14,262,000 (562.6%).
- Net loss of 8,878,000 reduced equity.
- New share issuances of 18,546,000 increased equity.
- Other factors increased equity by 4,594,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.88 Million | -52.85% |
| Share Issuances | $18.55 Million | +110.41% |
| Other Changes | $4.59 Million | +27.35% |
| Total Change | $- | 562.60% |
Book Value vs Market Value Analysis
This analysis compares Valion Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.12x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 58.24x to 0.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.01 | $0.81 | x |
| 2019-12-31 | $0.03 | $0.81 | x |
| 2020-12-31 | $0.02 | $0.81 | x |
| 2022-12-31 | $637.74 | $0.81 | x |
| 2023-12-31 | $41.51 | $0.81 | x |
| 2024-12-31 | $4.55 | $0.81 | x |
| 2025-12-31 | $6.65 | $0.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Valion Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -52.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.88x
- Recent ROE (-52.85%) is above the historical average (-366.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -1337.06% | -4207.19% | 0.15x | 2.10x | $-4.34 Million |
| 2019 | -340.41% | 0.00% | 0.00x | 2.00x | $-4.49 Million |
| 2020 | -102.02% | 0.00% | 0.00x | 1.04x | $-967.19K |
| 2022 | -278.13% | -548.70% | 0.31x | 1.62x | $-10.46 Million |
| 2023 | -230.28% | -701.02% | 0.23x | 1.44x | $-8.60 Million |
| 2024 | -223.08% | 0.00% | 0.00x | 1.11x | $-5.91 Million |
| 2025 | -52.85% | 0.00% | 0.00x | 1.88x | $-10.56 Million |
Industry Comparison
This section compares Valion Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $26,655,248
- Average return on equity (ROE) among peers: -103.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Valion Bio Inc (VBIO) | $16.80 Million | -1337.06% | 0.88x | $2.55 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $95.15 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $1.24 Billion |
| Abeona Therapeutics Inc (ABEO) | $-9.89 Million | 0.00% | 0.00x | $291.24 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $156.73 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $721.84 Million |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $827.15 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.02 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.51 Billion |
About Valion Bio Inc
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenesce… Read more